Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.
Kevans, David Gorman, Sheeona Tosetto, Miriam Sheahan, Kieran O'Donoghue, Diarmuid Mulcahy, Hugh O'Sullivan, Jacintha
Kevans, David
Gorman, Sheeona
Tosetto, Miriam
Sheahan, Kieran
O'Donoghue, Diarmuid
Mulcahy, Hugh
O'Sullivan, Jacintha
Advisors
Editors
Other Contributors
Date
2012-06
Date Submitted
Keywords
Other Subjects
Subject Mesh
Antineoplastic Agents
Apoptosis
Blotting, Western
Cell Hypoxia
Cell Line, Tumor
Cell Proliferation
Clusterin
Colorectal Neoplasms
Drug Resistance, Neoplasm
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Humans
Transfection
Apoptosis
Blotting, Western
Cell Hypoxia
Cell Line, Tumor
Cell Proliferation
Clusterin
Colorectal Neoplasms
Drug Resistance, Neoplasm
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Humans
Transfection
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
In vitro studies have shown that clusterin modulates treatment sensitivity in a number of human cancers; however, the interaction between clusterin expression and hypoxia in controlling treatment response in CRC has not previously been examined. The aim of this study was to assess the effect of clusterin overexpression in CRC cells on sensitivity to 5-fluorouracil (5-FU), oxaliplatin and FOLFOX treatment under normoxic and graded hypoxic conditions.
Language
en
ISSN
1941-6636
eISSN
ISBN
DOI
10.1007/s12029-011-9277-x
PMID
21487682